Osteoporosis drug impresses at bone meeting

An investigative biologic substantially reduces vertebral fracture risk and increases BMD in postmenopausal women with osteoporosis, a phase 3 trial has shown.

The drug, romosozumab, binds to the protein sclerostin, which has been shown to inhibit bone growth.

In a two-year randomised trial with over 7,000 women, romosozumab reduced new vertebral fractures within six months, compared